A B S T R A C T Although prostaglandins E2 and F2, have been suggested as mediators of the pulmonary hypertension seen after endotoxin infusion or during alveolar hypoxia, their precursors, the endoperoxides (prostaglandins G2 and H2) are much more potent vasoconstrictors in vitro. In this study we compared the effects of prostaglandin (PG)H2, a stable 9-methylene ether analogue of PGH2 (PGH2-A), PGE2, and PGF2a on pulmonary hemodynamics in awake sheep. The animals were prepared to allow for measurement of (a) 
A B S T R A C T Although prostaglandins E2 and F2, have been suggested as mediators of the pulmonary hypertension seen after endotoxin infusion or during alveolar hypoxia, their precursors, the endoperoxides (prostaglandins G2 and H2) are much more potent vasoconstrictors in vitro. In this study we compared the effects of prostaglandin (PG)H2, a stable 9-methylene ether analogue of PGH2 (PGH2-A), PGE2, and PGF2a on pulmonary hemodynamics in awake sheep. The animals were prepared to allow for measurement of (a) lung lymph flow; (b) plasma and lymph protein concentration; (c) systemic and pulmonary vascular pressures; and (d) cardiac output. We also determined the effect of prolonged PGH2-A infusions on lung fluid balance and vascular permeability by indicator dilution methods, and by assessing the response of lung lymph. Both PGH2 and PGH2-A caused a dose-related increase in pulmonary artery pressure: 0.25 ,ug/kg x min tripled pulmonary vascular resistance without substantially affecting systemic pressures. Both were 100 times more potent than PGE2 or PGF2,, in this preparation. ?GH2-A, as our analysis of lung lymph and indicator dilution measurements show, does not increase the permeability of exchanging vessels in the lung to fluid and protein. It does, however, augment lung fluid transport by increasing hydrostatic pressure in the pulmonary circulation. We conclude: (a) that PGH2 is likely to be an important mediator of pulmonary vasoconstriction; (b) its effects are probably not a result of its metabolites PGE2 or PGF,. INTRODUCTION The agents mediating the pulmonary hypertension seen with alveolar hypoxia and gram-negative endotoxin infusion have not been identified. Because prostaglandins (PG)l E2 and F2, are released from the lungs during these reactions, they have been implicated as the mediators, but neither is an impressive vasoconstrictor in vitro (1, 2) . In contrast, their precursors, the endoperoxides PGG2 and PGH2, are powerful vasoconstrictors, -100 times more potent in constricting isolated smooth muscle (3) .
Because the endoperoxides are unstable and difficult to synthesize in the large amounts needed for in vivo studies, we first used a stable 9-methylene ether analogue of PGH2 (PGH2-A; [15S] hydroxy-lla, 9a-[epoxymethano] prosta-5Z, 13E-dienoic acid, [4] ) to assess the effects of endoperoxides on pulmonary vascular pressures, permeability of the lung microcirculation, and lung fluid balance in awake sheep. We then prepared PGH2, itself, in amounts large enough for brief steady-state infusions, and compared its effects to those of the analogue, PGE2 and PGF2a,.
PGH2 and PGH2-A were potent vasoconstrictors, 100 times more potent than PGE2 and PGF2,. PGH2-A, as our studies of lung lymph and indicator dilution measurements showed, did not increase the permeability of exchanging vessels in the lung to fluid and protein, although it did augment fluid transport by increasing hydrostatic pressure in these vessels.
METHODS
Materials. We prepared PGH2 by incubating arachidonic acid with sheep seminal vesicle microsomes. After isolating PGH2 by silicic acid chromatography, we confirmed the structure by mass spectrometry (5, 6) . We stored PGH2 in an 'Abbreviations used in this paper: PG, prostaglandin; PGH2-A, stable 9-methylene ether analogue of PGH2. acetone solution at -60°C and infused it with normal saline so that the amount of acetone delivered was <0.1 ml over 15 min. This amount ofacetone infused alone had no effect on vascular pressures or lymph flow. PGH2 analogue, which was supplied by Upjohn Co., Kalamazoo, Mich. was synthesized as described by Bundy (4) . We stored PGH2-A in absolute ethanol solutions at 40C, then diluted it with normal saline shortly before an experiment.
PGE2 and PGF2<,, were also supplied by Upjohn Co. We dissolved them in normal saline and adjusted pH to between 6 and 7 with bicarbonate buffer before infusion.
Experimental preparation. We prepared sheep by a series of thoracotomies as described (7) (8) (9) . Through a left thoracotomy, we put catheters in the pulmonary artery and left atrium and a Doppler ultrasonic flow cuff (Park Electronics Laboratory, Beaverton, Oreg.) around the main pulmonary artery. In some sheep, we put a Foley balloon catheter in the left atrium. Several days later, through a right thoracotomy, we cannulated the efferent lymph vessel emerging from the caudal mediastinal lymph node, resected the tail of the node, and passed catheters into the thoracic aorta and vena cava through neck vessels. Because lymph flow from sheep prepared this way responds to changes in pulmonary venous pressure, but not to changes in systemic venous pressure, it comes primarily from the lungs (7) .
After the last operation, we waited until the lung lymph flow, vascular pressures, and cardiac output were stable and the lymph was free of blood before doing experiments. In several sheep, lymph flow stopped spontaneously. We (18) . 
Statistics
Where the summary data are given, we show the average -+SE of measurement. We compared the significance of data Tables I   and II and illustrated in Fig. 1 . Both substances caused a dose-related increase in pulmonary vascular resistance leading to a threefold increase in pulmonary artery pressure at the 0.25 ,ug/kg x min dose. There was a small, dose-related drop in cardiac output. Infusion of PGH2 into the left atrium caused no change in pulmonary or systemic pressures or cardiac output, but left atrial PGH2-A infusions caused pulmonary hemodynamic changes similar to intravenous infusion of the same substance.
PGE2 and PGF2, caused little change in pulmonary vascular resistance until the dose reached 10 ,ug/kg x min, almost 100 times the effective PGH2 dose (Fig.  2) . At higher doses, pulmonary arterial and left atrial pressure rose as cardiac output fell. At the higher doses the animals developed respiratory distress and often collapsed. Fig. 3 , infusion of PGH2-A caused a dose-related increase in lung lymph flow, corresponding to increases in pulmonary artery pressure. Although the lymph flow increased substantially at higher doses, the lymph protein concentration fell. These data are summarized in Table III . The fall in lymph protein concentration as lymph flow increases is a characteristic effect of high pressure (8) . In fact, the effect of PGH2-A and high left atrial pressure on All are indistinguishable (Fig. 4) (3, 20) suggest this potency of the endoperoxide, its specificity for the pulmonary circulation in vivo is unexpected. Few, if any, known endogenous sub- (1) and (2) are derived from the same population cannot be rejected (P > 0.30). Line (3) derived from studies of histamine infusion shows the characteristic failure of An to increase with lymph flow when vascular permeability is high.
Both will aggregate platelets in vitro (3, 5) , but their effects on pulmonary vascular resistance probably are not a result of intravascular platelet aggregation because: (a) the high pulmonary artery pressure produced by infusion of PGH2 and PGH2-A returned to normal within 5 min after the infusion was stopped; and (b) infusion of PGH2 into the left atrium had no apparent physiological effects. If platelet aggregation and vascular plugging were involved the effect should persist for longer than 5 min. From our data, we cannot determine whether the effects of PGH2 are a direct result of its action on the smooth muscle of the resistance vessels of the lung, or whether conversion to its metabolite thromboxane A2 is necessary first. Thromboxane A2 is more potent than PGH2 in contracting large arterial smooth muscle and in inducing aggregation ofplatelets in vitro (22, 23) . Because it is formed from PGH2 in the lung (24) , it is possible that the hemodynamic effects of PGH2 are mediated through this more active metabolite. Our finding that PGH2-A, the analogue (which is not metabolized to thromboxane A2), had effects similar to those of biosynthesized PGH2 suggests that PGH2 itself may cause vasoconstriction. However, if the analogue mimics thromboxane A2 physiologically, our conclusion that the identical vasoconstriction PGH2 and PGH2-A cause is an innate effect of both may be wrong. Instead, PGH2's conversion to, and PGH2-A's imitation of, thromboxane A2 could explain their common effect.
The response to infusion of exogenous PGH2 into the pulmonary circulation does not prove that PGH2, when synthesized in the lung, has an identical effect. This could occur if PGH2 is synthesized in amounts comparable to those infused and if PGH2 has access to the smooth muscle of the resistance vessels. The exquisite sensitivity of the pulmonary circulation to PGH2 suggests that amounts synthesized in the lung could be physiologically significant. Lung vessels would also Prostaglandin Endoperoxides and the Lung Circulation (9) . With histamine, the osmotic pressure difference at high lymph flow falls, but with serotonin, mechanically increased pulmonary venous pressure, and, as this study shows, PGH2-A infusion, the oncotic pressure difference between lymph and plasma increases as lymph flow increases (Fig. 4) 
